Overall and patient-level comparative effectiveness of dimethyl fumarate and fingolimod: A precision medicine application to the Observatoire Français de la Sclérose en Plaques registry. Issue 3 (July 2022)

• Record Type: Journal Article
• Authors: Simoneau, Gabrielle; Jiang, Xiaotong; Rollot, Fabien; Tian, Lu; Copetti, Massimiliano; Guéry, Matthieu; Ruiz, Marta; Vukusic, Sandra; de Moor, Carl; Pellegrini, Fabio
• Is Part Of: Multiple sclerosis journal, experimental, translational and clinical. Volume 8:Issue 3(2022)
• Publication Date: 2022-07
• Subjects: Comparative effectiveness -- dimethyl fumarate -- fingolimod -- precision medicine -- propensity score -- registry; Multiple sclerosis -- Periodicals; 616.834
• DOI: 10.1177/20552173221116591
• Languages: English
• ISSNs: 2055-2173

Abstract

Background: Comparing real-world effectiveness and tolerability of therapies for relapsing-remitting multiple sclerosis is increasingly important, though average treatment effects fail to capture possible treatment effect heterogeneity. With the clinical course of the disease being highly heterogeneous across patients, precision medicine methods enable treatment response heterogeneity investigations. Objective: To compare real-world effectiveness and discontinuation profiles between dimethyl fumarate and fingolimod while investigating treatment effect heterogeneity with precision medicine methods. Methods: Adults initiating dimethyl fumarate or fingolimod as a second-line therapy were selected from a French registry. The primary outcome was annualized relapse rate at 12 months. Seven secondary outcomes relative to discontinuation and disease progression were considered. A precision medicine framework was used to characterize treatment effect heterogeneity. Results: Annualized relapse rates at 12 months were similar for dimethyl fumarate and fingolimod. The odd of treatment persistence was 47% lower for patients treated with dimethyl fumarate relative to those treated with fingolimod (odds ratio: 0.53, 95% confidence interval: 0.39, 0.70). None of the five precision medicine scoring approaches identified treatment heterogeneity. Conclusion: These findings substantiated the similar effectiveness and different discontinuation profiles for dimethyl fumarate and fingolimod as a second-line therapy for relapsing-remitting multiple sclerosis, with no significant effect heterogeneity observed.